Trump’s push to onshore pharma manufacturing clouded by ‘lack of clarity’
A degree of uncertainty reigns over the implementation of regulations imposed by US President Donald Trump that aim to bolster pharmaceutical manufacturing in the US, market analysis suggests. Trump has signed a range of executive orders that aim to incentivise drugmakers to double-down on manufacturing infrastructure in the US. The most widely reported have been … Read more